Previous 10 | Next 10 |
iNKT cells have unique properties that could be therapeutic. MiNK Therapeutics has shown it can both manufacture and engineer iNKT cells. Preliminary data expected before year-end could push the stock price substantially higher. For further details see: MiNK Therapeutics...
LEXINGTON, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will host a hybrid webcast to discuss botensil...
AC Immune (ACIU) -32% as crenezumab fails in Alzheimer's study. Cango (CANG) -30%. Absci (ABSI) -14%. Hillstream BioPharma (HILS) -11%. Cepton (CPTN) -7%. Enservco Corporation (ENSV) -10%. Arcellx (ACLX) -10% on upsizing of follow-on public offering of 7M shares at $...
First RSV vaccine candidate to show statistically significant and clinically meaningful efficacy in adults aged 60 years and above Third AS01 adjuvanted vaccine containing QS-21 STIMULON to deliver meaningful clinical benefit against infections in a registrational program Global...
LEXINGTON, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that it has entered into 3 new clinical collaborations wit...
Data to be Presented in Heavily Pretreated MSS-CRC Speed and Innovation Core to Development Strategy Reduction of 20% in 2022 Operating Costs LEXINGTON, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipel...
Biotech companies spend a lot of money. They spend it on research and development, clinical trials, and (if they are lucky) marketing and a salesforce. Bringing a new pharmaceutical or medical device to market is an expensive proposition. In fact, it's fair to say that a lot of biotech comp...
Image source: The Motley Fool. Agenus (NASDAQ: AGEN) Q1 2022 Earnings Call May 10, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus (AGEN) Q1 2022 Earnings Call Transcript
Agenus Inc. (AGEN) Q1 2022 Earnings Conference Call May 9, 2022 08:30 ET Company Participants Christine Klaskin - Vice President of Finance, Principal Financial Officer & Principal Accounting Officer Dhan Chand - Scientific Director & Head of Drug Discovery Ethan Lovell - Chief Extern...
Agenus (NASDAQ:AGEN) stock rose May 10 after the company's Q1 results beat analysts' estimates. The company said it began cost containment measures with expected reductions in operating expenses in coming quarters. Q1 total revenue grew +121.36% Y/Y to $25.94M. "In the current challengin...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...